These means, however, include considerable individual variability. Food increases the rate and extent of absorption of amiodarone hydrochloride. The effects of food upon the bioavailability of amiodarone hydrochloride have been studied in 30 healthy subjects who received a single mg dose immediately after consuming a high-fat meal and following an overnight fast.
The area under the plasma concentration-time curve AUC and the peak plasma concentration C max of amiodarone increased by 2. One major metabolite of amiodarone hydrochloride, DEA, has been identified in man; it accumulates to an even greater extent in almost all tissues.
No data are available on the activity of DEA in humans, but in animals, it has significant electrophysiologic and antiarrhythmic effects generally similar to amiodarone itself. The development of maximal ventricular class III effects after oral amiodarone hydrochloride administration in humans correlates more closely with DEA accumulation over time than with amiodarone accumulation. Following single dose administration in 12 healthy subjects, amiodarone hydrochloride exhibited multi-compartmental pharmacokinetics with a mean apparent plasma terminal elimination half-life of 58 days range 15 to days for amiodarone and 36 days range 14 to 75 days for the active metabolite DEA.
A much slower terminal plasma-elimination phase shows a half-life of the parent compound ranging from 26 to days, with a mean of approximately 53 days and most patients in the to day range. In the absence of a loading-dose period, steady-state plasma concentrations, at constant oral dosing, would therefore be reached between and days, with an average of days. For the metabolite, the mean plasma-elimination half-life was approximately 61 days. These data probably reflect an initial elimination of drug from well-perfused tissue the 2.
The considerable inter-subject variation in both phases of elimination, as well as uncertainty as to what compartment is critical to drug effect, requires attention to individual responses once arrhythmia control is achieved with loading doses because the correct maintenance dose is determined, in part, by the elimination rates.
Individualize maintenance doses of amiodarone hydrochloride [see Dosage and Administration 2 ]. The CYP3A isoenzyme is present in both the liver and intestines. Amiodarone is eliminated primarily by hepatic metabolism and biliary excretion and there is negligible excretion of amiodarone or DEA in urine. Neither amiodarone nor DEA is dialyzable. After a single dose of intravenous amiodarone to cirrhotic patients, significantly lower C max and average concentration values are seen for DEA, but mean amiodarone levels are unchanged.
Although no dosage adjustment for patients with renal, hepatic, or cardiac abnormalities has been defined during chronic treatment with oral amiodarone, close clinical monitoring is prudent for elderly patients and those with severe left ventricular dysfunction. Reduces enterohepatic circulation of amiodarone thereby increasing its elimination. This results in reduced amiodarone serum levels and half-life. A non-sedating antihistaminic, is metabolized primarily by CYP3A and its metabolism can be inhibited by amiodarone.
The metabolism of cyclophosphamide may be inhibited by amiodarone. An inactive thienopyridine prodrug, is metabolized in the liver by CYP3A to an active metabolite. A potential interaction between clopidogrel and amiodarone resulting in ineffective inhibition of platelet aggregation has been reported.
When taken concomitantly with oral amiodarone can result in elevated serum concentration of dabigatran. Amiodarone inhibits CYP2D6. The incidence of thyroid tumors was greater than control even at the lowest dose level tested, i. Mutagenicity studies Ames, micronucleus, and lysogenic tests with amiodarone hydrochloride were negative. Amiodarone hydrochloride tablets, for oral administration, are available as. Dispense contents in a tight, light-resistant container as defined in the USP, with a child-resistant closure as required.
For current full prescribing information, please visit www. Advise females of reproductive potential to inform their prescriber of a known or suspected pregnancy [see Use in Specific Populations 8. Advise women that breastfeeding is not recommended during treatment with amiodarone hydrochloride [see Use in Specific Populations 8. Advise patients to seek medical attention if they experience the signs and symptoms of pulmonary toxicity, worsening arrhythmia, bradycardia, visual impairment, or hypo- and hyperthyroidism.
What is the most important information I should know about amiodarone hydrochloride tablets? Amiodarone hydrochloride tablets can cause serious side effects that can lead to death including:. Call your healthcare provider or get medical help right away if you have any of the following symptoms during treatment with amiodarone hydrochloride tablets:. Amiodarone hydrochloride tablets should be started in a hospital so that your medical condition can be carefully monitored. Amiodarone hydrochloride tablets should only be used to treat people who have been diagnosed with life-threatening heartbeat problems called ventricular arrhythmias, when other treatments did not work or you cannot tolerate them.
Amiodarone hydrochloride tablets can cause other serious side effects. Talk with your healthcare provider before you stop taking amiodarone hydrochloride tablets. You may still have side effects after stopping amiodarone hydrochloride tablets because the medicine stays in your body for months after treatment is stopped. You should have regular check-ups, blood tests, chest x-rays before and during treatment with amiodarone hydrochloride tablets to check for serious side effects.
You should also have lung function tests before starting treatment with amiodarone hydrochloride tablets. Amiodarone hydrochloride tablets are a prescription medicine used to treat people who have been diagnosed with life-threatening heartbeat problems called ventricular arrhythmias, when other treatment did not work or you cannot tolerate them.
Before taking amiodarone hydrochloride tablets tell your doctor about all of your medical conditions, including if you:. Tell your healthcare provider about all the medicines you take including prescription and over-the-counter medicines, vitamins, and herbal supplements.
Amiodarone hydrochloride tablets and certain other medicines can affect with each other and cause serious side effects. You can ask your pharmacist for a list of medicines that interact with amiodarone hydrochloride tablets.
What should I avoid while taking amiodarone hydrochloride tablets? What are the possible side effects of amiodarone hydrochloride tablets? Amiodarone hydrochloride tablets can cause serious side effects, including:. Amiodarone hydrochloride tablets may affect fertility in males and females. It is not known if the effects are reversible. Talk to your healthcare provider if you have concerns about fertility. These are not all the possible side effects of amiodarone hydrochloride tablets. For more information, ask your healthcare provider or pharmacist.
Call your doctor for medical advice about side effects. Keep amiodarone hydrochloride tablets and all medicines out of the reach of children.
General information about the safe and effective use of amiodarone hydrochloride tablets. Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use amiodarone hydrochloride tablets for a condition for which they were not prescribed. Do not give amiodarone hydrochloride tablets to other people, even if they have the same symptoms that you have.
They may harm them. You can ask your pharmacist or healthcare provider for information about amiodarone hydrochloride tablets that was written for health professionals. For more information call or go to www. What are the ingredients in amiodarone hydrochloride tablets? For Medication Guides, please visit www. DailyMed will deliver notification of updates and additions to Drug Label information currently shown on this site through its RSS feed.
DailyMed will deliver this notification to your desktop, Web browser, or e-mail depending on the RSS Reader you select to use. Due to inconsistencies between the drug labels on DailyMed and the pill images provided by RxImage , we no longer display the RxImage pill images associated with drug labels.
We anticipate reposting the images once we are able identify and filter out images that do not match the information provided in the drug labels. View Package Photos. Drug Label Info. NDC National Drug Code - Each drug product is assigned this unique number which can be found on the drug's outer packaging. These highlights do not include all the information needed to use Amiodarone hydrochloride Tablets safely and effectively. See full prescribing information for Amiodarone hydrochloride Tablets.
Amiodarone hydrochloride Tablets, for oral use. Initial U. Approval: Utilize alternative agents first. Administration Administer amiodarone hydrochloride consistently with regard to meals [see Clinical Pharmacology Supplemental oxygen is appropriate for any patient exhibiting signs of LAST, but for patients with apnea, hemodynamically unstable arrhythmias, or cardiac arrest, immediate, more aggressive airway management or circulatory support is required.
The goals are to maintain pulmonary ventilation and adequate organ perfusion with well-oxygenated blood and to avoid further acidosis until initiation of lipid emulsion therapy.
Before the introduction of lipid emulsion resuscitation, the treatment of severe cardiac toxicity was limited to ACLS and cardiopulmonary bypass. The use of vasopressors during resuscitation potentially worsened acidosis and arrhythmias. The cardiopulmonary bypass had been used in some cases; unfortunately, not all hospitals have that capability. The idea that a lipid-rich substance has the potential to reverse the effects of certain drugs began in the s, when several animal experiments demonstrated that intravenous administration of an oil emulsion decreased the duration of action of thiopental or decreased the free fraction of chlorpromazine in blood.
Serendipitously, in , the case of LAST in a young woman with isovaleric acidemia and carnitine deficiency inspired a series of animal experiments. So, Weinberg et al hypothesized that overloading cells with exogenous fatty acids by infusing a lipid emulsion would exacerbate LA toxicity. Surprisingly, the opposite was seen. Infusing a fat emulsion decreased and even reversed LA toxicity.
In , the first successful resuscitation of a human patient with a lipid emulsion was reported. Since then, there have been many clinical reports describing effective reversal of LAST in adults and children.
Treatment of toxicity with an intravenous lipid emulsion has been termed lipid resuscitation therapy LRT. However, the scavenging effect is not sufficient to explain the rapid recovery. A second effect occurs whereby in laboratory models infusing the lipid emulsion increases cardiac output through a combination of volume and direct cardiotonic effects to improve cardiac output once the cardiac concentration of drug drops below ion channel—blocking thresholds.
The lipid emulsion LD50 median lethal dose tested in a rat model was found to be much higher than the doses used for lipid rescue in humans. Nonetheless, actual reported side effects are limited to bronchospasm, hyperamylasemia, and laboratory measurement interference.
Transaminitis, hepatosplenomegaly, and bacterial contamination are typically associated with prolonged use of a lipid emulsion and do not play a role in the short-term administration for LAST. Last, as mentioned, one should exercise caution with the use of propofol in this setting: It is not a substitute for a lipid emulsion. There is insufficient lipid content in standard sedating or antiseizure doses of propofol to exert a benefit in the overdose setting; however, propofol can compromise CV stability.
The guidelines stress the importance of immediate cardiopulmonary resuscitation and provide a detailed algorithm for the dosing and administration of the lipid emulsion. Timely use of the LRT, at the earliest signs of toxicity, can improve resuscitative efforts and decrease the amount of vasopressors used.
As with any life-threatening emergency, securing intravenous access is essential; however, intraosseous administration of lipid emulsion is a possible alternative if intravenous access proves problematic. As always, the best treatment is prevention.
This is especially true for LAST. Dating in Germany will either make it more so or raise the chance to finally get the partner you've been looking for all along. Dating for expats info. Living in Germany is an incredible opportunity to rediscover and reinvent yourself, including the romantic side of your life. Transcending cultural differences and customs is just a small step to achieve that. Online Dating Guide. No matter who you ask, you will get the same answer: dating nowadays is hard.
Role of patient preference Parental preference should be considered in the decision to see a specialist and in the choice of specialist Exclusions IHs not considered high risk Strength Strong recommendation Key references 19 — Grade B. Benefits Avoid the cost, risk of sedation, and radiation associated with unnecessary imaging Risks, harm, cost Potential misdiagnosis if imaging is not performed Benefit-harm assessment Benefits outweigh harm Intentional vagueness None Role of patient preference Minimal; when parental anxiety is significant, ultrasonography is a low-cost and low-risk means of confirming the diagnosis Exclusions None Strength Moderate recommendation Key references 8 , 46 — Grade C.
Benefits Select the appropriate imaging study to aid in diagnosis and identify associated abnormalities; avoid ionizing radiation and sedation Risks, harm, cost Risk that ultrasonography may not be sufficiently diagnostic or may result in the misdiagnosis of a lesion believed to represent an IH Benefit-harm assessment Benefits outweigh harms Intentional vagueness None Role of patient preference Minimal Exclusions None Strength Weak recommendation Key references 47 , Benefits Select the appropriate imaging study to aid in diagnosis and identify associated abnormalities; avoid ionizing radiation and sedation Risks, harm, cost Risk of sedation or general anesthesia Cost of MRI but offers greater diagnostic sensitivity Benefit-harm assessment Benefits outweigh harms Intentional vagueness None Role of patient preference Minimal Exclusions None Strength Moderate recommendation Key references 46 , 51 — Grade A.
Benefits Improve IH treatment; avoid adverse effects associated with oral steroid therapy Risks, harm, cost Occurrence of adverse effects associated with propranolol use see KAS 3D ; medication cost and cost of hospitalization if drug is initiated while infant is an inpatient Benefit-harm assessment Benefits outweigh harms Intentional vagueness None Role of patient preference Parents should be involved in shared decision-making regarding treatment.
Propranolol 95 88—99 Topical timolol 62 39—83 Intralesional triamcinolone 58 21—93 Oral steroid 43 21—66 Control 6 1— Benefits The recommended doses have been associated with high clearance rates of IH Risks, harm, cost Response rates for higher or lower doses have not been well studied Benefit-harm assessment Benefits outweigh harms Intentional vagueness None Role of patient preference Parents will be involved in the decision about dosing in the setting of PHACE syndrome or the occurrence of adverse effects Exclusions See KAS 3A; dosing may be modified if comorbidities exist Strength Moderate recommendation Key references 1 , 46 , 61 , TABLE 14 Key Action Statement 3C: Clinicians should counsel that propranolol be administered with or after feeding and that doses be held at times of diminished oral intake or vomiting to reduce the risk of hypoglycemia grade X, strong recommendation.
Benefits Reduce the likelihood of adverse reactions Risks, harm, cost Risk that parents will decline therapy because of concerns about potential medication adverse effects Benefit-harm assessment Benefits outweigh harms Intentional vagueness None Role of patient preference None Exclusions None Strength Strong recommendation Key references 46 , 60 , 61 , 76 , 78 — TABLE 15 Key Action Statement 3D: Clinicians should evaluate patients for and educate caregivers about potential adverse effects of propranolol, including sleep disturbances, bronchial irritation, and clinically symptomatic bradycardia and hypotension grade X, strong recommendation.
Benefits Recognition of adverse effects of propranolol treatment Risks, harm, cost Risk of caregivers declining medical therapy because of concern about potential adverse effects Benefit-harm assessment Benefits outweigh harms Intentional vagueness None Role of patient preference None Exclusions None Strength Strong recommendation Key references 3 , 46 , 61 , 76 , 80 , 85 — Benefits Modest benefit in IH clearance; medication cost is low Risks, harm, cost Clinically important harms; cost associated with the evaluation and treatment of adverse effects Intentional vagueness None Benefit-harm assessment Benefits outweigh harms Role of patient preference Shared decision-making regarding treatment Exclusions None Strength Moderate recommendation Key references 46 , 70 , Benefits Modest benefit in IH clearance Risks, harm, cost Clinically important harms; cost of medication, visits for injection; risk of anesthesia if used Benefit-harm assessment Benefits outweigh harms in selected clinical situations Intentional vagueness None Role of patient preference Shared decision-making regarding route of drug delivery Exclusions None Strength Moderate recommendation Key references 3 , 46 , , — Benefit Modest benefit in IH clearance Harm Low but possible risk of local irritation, sleep disturbance, cold extremities, bronchospasm, and bradycardia, with more caution needed in preterm infants and those without intact skin ie, ulceration Cost Cost of medication Benefits-harm assessment Benefits outweigh harms Value judgments None Role of patient preference Parents have a significant role in decision-making regarding the desire to treat small superficial lesions for which timolol may be effective Intentional vagueness None Exclusions Lesions that are large size, significantly elevated, or life-threatening Strength Moderate recommendation Key references 40 , 46 , 85 , — TABLE 20 Key Action Statement 5: Clinicians should educate parents of infants with an IH about the condition, including the expected natural history, and its potential for causing complications or disfigurement grade X, strong recommendation.
Benefits Promotes parent satisfaction and understanding, may reduce medication errors, may improve clinical outcomes Risks, harm, cost May increase parental anxiety because of the need to administer medication; time spent in education, may increase health care costs because of the need for follow-up visits Benefit-harm assessment Benefits outweigh harms Intentional vagueness None Role of parental preferences Essential; shared decision-making regarding the need for treatment is vital Exclusions None Strength Strong recommendation Key references 21 , 22 , Other important evidence gaps should be highlighted, including the following:.
Are pediatric trainees receiving adequate training in risk stratification and management of IHs? Treatment of infantile haemangiomas: recommendations of a European expert group. Search ADS. Consensus statement for the treatment of infantile haemangiomas with propranolol. Risk factors for mortality in patients with multifocal and diffuse hepatic hemangiomas. Severe hypothyroidism caused by type 3 iodothyronine deiodinase in infantile hemangiomas. Prospective study of the frequency of hepatic hemangiomas in infants with multiple cutaneous infantile hemangiomas.
Impact of screening for hepatic hemangiomas in patients with multiple cutaneous infantile hemangiomas. Risk factors for amblyopia in children with capillary hemangiomas of the eyelids and orbit. Multicenter prospective study of ulcerated hemangiomas [published correction appears in J Pediatr. Segmental hemangioma of infancy complicated by life-threatening arterial bleed. LUMBAR: association between cutaneous infantile hemangiomas of the lower body and regional congenital anomalies.
Risk factors for degree and type of sequelae after involution of untreated hemangiomas of infancy. Growth characteristics of infantile hemangiomas: implications for management. Infantile hemangiomas with minimal or arrested growth: a retrospective case series.
Management of congenital subglottic hemangioma: trends and success over the past 17 years. Skin patterns associated with upper airway infantile haemangiomas: a retrospective multicentre study. Gastrointestinal bleeding in infantile hemangioma: a complication of segmental, rather than multifocal, infantile hemangiomas.
Infantile hemangiomas involving the neuraxis: clinical and imaging findings. Orbit and eyelid hemangiomas: is there a relationship between location and ocular problems? Visual development in infants: visual complications of periocular haemangiomas. PHACE syndrome. The association of posterior fossa brain malformations, hemangiomas, arterial anomalies, coarctation of the aorta and cardiac defects, and eye abnormalities. Growing up with a facial hemangioma: parent and child coping and adaptation.
Distribution, clinical characteristics, and surgical treatment of lip infantile hemangiomas. Infantile hemangioma with minimal or arrested growth: further observations on clinical and histopathologic findings of this unique but underrecognized entity. Reticular infantile hemangiomas with minimal or arrested growth associated with lipoatrophy. Ultrasonography as an objective tool for assessment of infantile hemangioma treatment with propranolol.
Arterial spin-labeled perfusion for vascular anomalies in the pediatric head and neck. Infantile hepatic hemangioma: role of dynamic contrast-enhanced magnetic resonance angiography. Prospective study of spinal anomalies in children with infantile hemangiomas of the lumbosacral skin. Spinal dysraphism associated with the cutaneous lumbosacral infantile hemangioma: a neuroradiological review. Neonatal lumbosacral ulceration masking lumbosacral and intraspinal hemangiomas associated with occult spinal dysraphism.
Safety of oral propranolol for the treatment of infantile hemangioma: a systematic review. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference.
Decreased eNOS protein expression in involuting and propranolol-treated hemangiomas. Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action. The use of propranolol in the treatment of infantile haemangiomas: an update on potential mechanisms of action.
Oral prednisolone for infantile hemangioma: efficacy and safety using a standardized treatment protocol. Role of propranolol in ulcerated haemangioma of head and neck: a prospective comparative study. Propranolol versus captopril in the treatment of infantile hemangioma IH : a randomized controlled trial.
Therapeutic superiority of combined propranolol with short steroids course over propranolol monotherapy in infantile hemangioma. Oral atenolol therapy for proliferating infantile hemangioma: a prospective study. A randomized, controlled trial of oral propranolol in infantile hemangioma.
Stroke in children with posterior fossa brain malformations, hemangiomas, arterial anomalies, coarctation of the aorta and cardiac defects, and eye abnormalities PHACE syndrome: a systematic review of the literature.
Hypoglycemia as a result of propranolol during treatment of infantile hemangioma: a case report. Hypoglycemia in children taking propranolol for the treatment of infantile hemangioma.
Propranolol was effective in treating cutaneous infantile haemangiomas in Thai children. Propranolol treatment for infantile hemangioma: a case series of sixty-two patients.
Initial experience with a multidisciplinary strategy for initiation of propranolol therapy for infantile hemangiomas. Is propranolol safe and effective for outpatient use for infantile hemangioma? A prospective study of cases from one center in China. Twenty-four-hour hospitalization for patients initiating systemic propranolol therapy for infantile hemangiomas—is it indicated?
Propranolol in infantile haemangioma: simplifying pretreatment monitoring. Predicting complications with pretreatment testing in infantile haemangioma treated with oral propranolol. Oral propranolol combined with topical timolol for compound infantile hemangiomas: a retrospective study.
Is cardiovascular evaluation necessary prior to and during beta-blocker therapy for infantile hemangiomas? Adverse effects of propranolol when used in the treatment of hemangiomas: a case series of 28 infants. Treatment of severe infantile hemangiomas with propranolol: an evaluation of the efficacy and effects of cardiovascular parameters in 25 consecutive patients.
Tissue levels of several radiolabelled beta-adrenoceptor antagonists after intravenous administration in rats.
Child development after maternal tocolysis with beta-sympathomimetic drugs. Propranolol and central nervous system function: potential implications for paediatric patients with infantile haemangiomas.
Reconsidering the use of propranolol in the treatment of cosmetic infantile hemangiomas. Use of propranolol for treatment of infantile haemangiomas in an outpatient setting. Propranolol treatment of infantile hemangiomas does not negatively affect psychomotor development.
Propranolol treatment of infantile hemangioma IH is not associated with developmental risk or growth impairment at age 4 years.
Oral corticosteroid use is effective for cutaneous hemangiomas: an evidence-based evaluation. Infantile hemangioma: treatment with short course systemic corticosteroid therapy as an alternative for propranolol.
Intralesional corticosteroid therapy for childhood cutaneous hemangiomas. Intralesional corticosteroid therapy in proliferating head and neck hemangiomas: a review of cases. Efficacy of intralesional steroid injection in head and neck hemangioma: a systematic review. Induced resolution of cavernous hemangiomas following prednisolone therapy.
The treatment of periorbital infantile hemangioma with intralesional corticosteroid. Visual acuity and astigmatism in periocular infantile hemangiomas treated with oral beta-blocker versus intralesional corticosteroid injection. Adrenal suppression and failure to thrive after steroid injections for periocular hemangioma.
Adrenal suppression after corticosteroid injection of periocular hemangiomas. Central retinal artery occlusion associated with periocular corticosteroid injection for juvenile hemangioma. Bilateral retinal embolization associated with intralesional corticosteroid injection for capillary hemangioma of infancy.
Diagnosis and treatment of an ophthalmic artery occlusion during an intralesional injection of corticosteroid into an eyelid capillary hemangioma. High injection pressure during intralesional injection of corticosteroids into capillary hemangiomas.
RCT of timolol maleate gel for superficial infantile hemangiomas in 5- to week-olds. Timolol maleate 0. A controlled study of topical 0.
Adverse events in young and preterm infants receiving topical timolol for infantile hemangioma. The safety and efficacy of glaucoma medication in the pediatric population.
Topical treatment for capillary hemangioma of the eyelid using beta-blocker solution. Treatment of superficial infantile hemangiomas with timolol: evaluation of short-term efficacy and safety in infants. Topical timolol maleate 0. Treatment of small superficial haemangioma with timolol 0.
Dramatic shift in the infantile hemangioma treatment paradigm at a single institution. Topical timolol for infantile hemangiomas: evidence for efficacy and degree of systemic absorption. Cardiorespiratory reaction to timolol maleate in a pediatric patient: a case report.
Can ophthalmic drops cause central nervous system depression and cardiogenic shock in infants? Topical timolol maleate for treatment of infantile haemangiomas: preliminary results of a prospective study.
Experience with topical timolol maleate for the treatment of ulcerated infantile hemangiomas IH. Infantile hemangioma: clinical assessment of the involuting phase and implications for management.
Randomised controlled study of early pulsed dye laser treatment of uncomplicated childhood haemangiomas: results of a 1-year analysis. Complications following pulsed dye laser treatment of superficial hemangiomas. Does the pulsed tunable dye laser have a role in the management of infantile hemangiomas? The psychosocial impact of an infantile haemangioma on children and their parents. Information about infantile hemangiomas on the Internet: how accurate is it?
Cellular markers that distinguish the phases of hemangioma during infancy and childhood. Propranolol treatment of infantile hemangiomas: anticipatory guidance for parents and caretakers [published correction appears in Pediatr Dermatol.
Prospective study of infantile haemangiomas: incidence, clinical characteristics and association with placental anomalies. Use of the Hemangioma Severity Scale to facilitate treatment decisions for infantile hemangiomas. Utility of the Hemangioma Severity Scale as a triage tool and predictor of need for treatment. Measuring the severity of infantile hemangiomas: instrument development and reliability.
Frommelt, MD, Pediatric Cardiology. Supplemental Information - pdf file. Comments Icon Comments 0. View Metrics. Citing articles via Web Of Science Email alerts Article Activity Alert. News Latest News Archive. Close Modal. This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.
Consult early by 1 month of age for lesions that are potentially high risk because of the following associations Table 3 :.
0コメント